Zhejiang East Asia Pharmaceutical Co., Ltd.

Primary objective: To study the pharmacokinetics of the test preparation trimebutine maleate tablets (specification: 0.2g/tablet, produced by Zhejiang East Asia Pharmaceutical Co., Ltd.) and the reference preparation trimebutine maleate tablets (Debridat®, specification: 200mg/tablet; produced by FARMEA) in healthy subjects after single oral administration in fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in fasting and fed state. Secondary objective: To study the safety of the test preparation trimebutine maleate tablets and the reference preparation trimebutine maleate tablets in healthy subjects.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of Tedizolid Phosphate Tablets (Specification: 200 mg) produced by Zhejiang East Asia Pharmaceutical Co., Ltd. and Tedizolid Phosphate Tablets (trade name: SIVEXTRO®; specification: 200 mg) produced by MSD Pharma (Singapore) Pte Ltd and manufactured by Patheon Inc. after a single oral dose in healthy Chinese subjects under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation (specification: 200 mg) and reference preparation (trade name: SIVEXTRO®; specification: 200 mg) of Tedizolid Phosphate Tablets in healthy Chinese subjects after a single oral dose.

Main objective: To use epalrestat tablets provided by Zhejiang East Asia Pharmaceutical Co., Ltd. as the test preparation and compare their absorption rate and extent in healthy humans with those of epalrestat tablets (trade name: KINEDAK®, reference preparation) certified by Alpharestat Pharmaceuticals Co., Ltd. according to the relevant provisions of bioequivalence studies, and to investigate the bioequivalence of the two preparations in humans.